<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161459</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1004</org_study_id>
    <nct_id>NCT01161459</nct_id>
  </id_info>
  <brief_title>Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid</brief_title>
  <official_title>Research Institute of Nephrology, Jinling Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus
      steroid in the treatment of membranous nephropathy.

      To investigate the safety and tolerability of Tripterygium wilfordii plus steroid
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults.
      Over the past decade, a number of studies have reported therapeutic efficacy for treatment
      with tacrolimus plus steroid in patients with nephrotic syndrome including patients with
      membranous nephropathy. This study will evaluate the safety and effectiveness of a
      traditional herbal extraction, Tripterygium wilfordii, plus steroid in reducing the amount of
      protein in the urine in patients with membranous nephropathy. A hundred patients with
      biopsy-proven membranous nephropathy will be recruited. They will be screened with a medical
      history, physical examination, blood tests, and an examination for infection, cancers, and
      other conditions that can cause membranous nephropathy. The investigators plan to conduct an
      open-label study of the efficacy and safety of Tripterygium wilfordii in the treatment of
      membranous nephropathy. Half of them will be treated with oral Tripterygium wilfordii plus
      steroids for 6 months, followed by 6 months of maintenance, and the other half treated with
      tacrolimus plus steroid as positive contrast. Proteinuria, renal function will be monitored.
      Complete remission is defined as 24-hour urinary protein excretion to less than 0.4 mg/day
      and serum albumin&gt;35g/L. This study will explore the potential role of Tripterygium wilfordii
      in the treatment of membranous nephropathy, it's cost less .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of CR and PR of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerabilitysteroid</measure>
    <time_frame>18 months</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Tripterygium wilfordii</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK506</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium wilfordii</intervention_name>
    <description>Tripterygium wilfordii 120mg/d Prednisone 30mg/d</description>
    <arm_group_label>Tripterygium wilfordii</arm_group_label>
    <other_name>TW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506</intervention_name>
    <description>capsule</description>
    <arm_group_label>FK506</arm_group_label>
    <other_name>Tacrolimus + Prednisone 30mg/d</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy-proven idiopathic membranous nephropathy

          2. Nephrotic syndrome with proteinuria ( &gt; 3.5 g/day) and serum albumin &lt; 30 g/dl

          3. Age 18-65 years with informed consent

        Exclusion Criteria:

          1. Patient with elevated serum creatinine concentration

          2. Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil,
             levamisole, methotrexate, or nitrogen mustard in the last 90 days

          3. Active/serious infection

          4. Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

          5. Patient who is diabetic

          6. Patient is allergic or intolerant to macrolide antibiotics or tacrolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Idiopathic Membranous Nephropathy</keyword>
  <keyword>Treatment</keyword>
  <keyword>FK506</keyword>
  <keyword>Tripterygium wilfordii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

